Filed with ASX · · 1 page · English
Cynata Therapeutics Limited has announced a consultancy agreement with Lir Bio Advisory Pty Ltd for services provided by Dr Kilian Kelly, a non-executive director of the Company. The agreement includes a monthly fee structure, with payments split between cash and performance rights, pending shareholder approval. The consultancy will focus on maintaining existing assets and exploring new opportunities for the Company.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX ANNOUNCEMENT 30 October 2026 Consultancy Agreement Melbourne, Australia; 30 October 2026: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), advises that it has entered into an agreement with Lir Bio Advisory Pty Ltd for provision of consultancy services by Dr...
Cynata Therapeutics Limited on 6ix
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics